A survey of current trends in computational drug repositioning

Briefings in Bioinformatics

Volumn 17, Issue 1, 2016, Pages 2-12

  Li, Jiao ^a   Zheng, Si ^a   Chen, Bin ^b   Butte, Atul J ^c   Swamidass, S Joshua ^d   Lu, Zhiyong ^e  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chemical structure; Computational drug repositioning; Drug combination; Genome; Integrative strategies; Phenome; Prediction validation

Indexed keywords

DRUG COMBINATION;

BIOLOGY; CHEMICAL STRUCTURE; DATA MINING; DRUG COMBINATION; DRUG REPOSITIONING; GENOMICS; HUMAN; MACHINE LEARNING; PHENOTYPE; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TRENDS;

COMPUTATIONAL BIOLOGY; DATA MINING; DRUG COMBINATIONS; DRUG REPOSITIONING; GENOMICS; HUMANS; MACHINE LEARNING; MOLECULAR STRUCTURE; PHENOTYPE; SURVEYS AND QUESTIONNAIRES;

EID: 84960079810     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbv020     Document Type: Article

References (101)

1. Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov 2004;3(5):451-6.
2. Dickson M, Gagnon JP. The cost of new drug discovery and development. Discov Med 2004;4(22):172-9.
3. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9(3):203-14.
4. Shaughnessy AF. Old drugs, new tricks. BMJ 2011;342:d741.
5. Graul AI, Cruces E, Stringer M. The year's new drugs & biologics, 2013: Part I. Drugs Today (Barc) 2014;50(1):51-100.
6. Shameer K, Readhead B, Dudley JT. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification. Curr Top Med Chem 2015;15(1): 5-20.
7. Power A, Berger AC, Ginsburg GS. Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity. JAMA 2014;311(20):2063-4.
8. Bolgar B, Arany A, Temesi G. et al., Drug repositioning for treatment of movement disorders: from serendipity to rational discovery strategies. Curr Top Med Chem 2013;13(18): 2337-63.
9. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26(5):495-511.
10. Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011;12(4):303-11.
11. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009;462(7270):175-81.
12. Ha S, Seo YJ, Kwon MS, et al. IDMap: facilitating the detection of potential leads with therapeutic targets. Bioinformatics 2008;24(11):1413-15.
13. von Eichborn J, Murgueitio MS, Dunkel M, et al. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res 2011;39:D1060-6.
14. Gloeckner C, Garner AL, Mersha F, et al. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc Natl Acad Sci USA 2010;107(8): 3424-9.
15. Iorio F, Bosotti R, Scacheri E, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 2010;107(33):14621-6.
16. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313(5795): 1929-35.
17. Vidovic D, Koleti A, Schurer SC. Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems- level drug action. Front Genet 2014;5:342.
18. Barrett T, Suzek TO, Troup DB, et al. NCBI GEO: mining millions of expression profiles-database and tools. Nucleic Acids Res, 2005;33:D562-6.
19. Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011;3(96):96ra76.
20. Jahchan NS, Dudley JT, Mazur PK, et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013;3(12):1364-77.
21. Iorio F, Rittman T, Ge H, et al. Transcriptional data: a new gateway to drug repositioning? Drug Discov Today 2013; 18(7-8):350-7.
22. Pacini C, Iorio F, Goncalves E, et al. DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics 2013;29(1):132-4.
23. Dennis G, Jr., Sherman BT, Hosack DA, et al., DAVID: database for annotation, visualization, and integrated discovery. Genome Biol, 2003;4(5):P3.
24. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102(43):15545-50.
25. Ding XM. MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chin J Cancer 2014; 33(3):140-7.
26. Wen X, Deng FM, Wang J. MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer. Am J Clin Exp Urol 2014;2(3):219-30.
27. Xing Z, Li D, Yang L, et al. MicroRNAs and anticancer drugs. Acta Biochim Biophys Sin (Shanghai) 2014;46(3):233-9.
28. Liu Z, Borlak J, Tong W. Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis. Genome Med 2014;6(12):94.
29. Jiang W, Chen X, Liao M, et al., Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. Sci Rep 2012;2:282.
30. Rukov JL, Wilentzik R, Jaffe I, et al. Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform 2014;15(4): 648-59.
31. Liu X, Wang S, Meng F, et al. SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression. Bioinformatics 2013;29(3):409-411.
32. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483(7391):570-5.
33. Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506(7488):376-81.
34. Sanseau P, Agarwal P, Barnes MR, et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol 2012;30(4):317-20.
35. Hebbring SJ. The challenges, advantages and future of phenome- wide association studies. Immunology 2014;141(2): 157-65.
36. Denny JC, Bastarache L, Ritchie MD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol 2013;31(12):1102-10.
37. Yang L, Agarwal P. Systematic drug repositioning based on clinical side-effects. PLoS One 2011;6(12):e28025.
38. Ye H, Liu Q, Wei J. Construction of drug network based on side effects and its application for drug repositioning. PLoS One 2014;9(2):e87864.
39. Bisgin H, Liu Z, Fang H, et al. A phenome-guided drug repositioning through a latent variable model. BMC Bioinformatics 2014;15:267.
40. Kuhn M, Campillos M, Letunic I, et al. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010;6: 343.
41. Hoehndorf R, Oellrich A, Rebholz-Schuhmann D, et al. Linking PharmGKB to phenotype studies and animal models of disease for drug repurposing. Pac Symp Biocomput 2012: 388-399.
42. Flintoft L. Disease genetics: phenome-wide association studies go large. Nat Rev Genet 2014;15(1):2.
43. Vencken PM, Kriege M, Hooning M, et al. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: implications for counseling. Cancer 2013;119(5):955-62.
44. Hyman DM, Zhou Q, Iasonos A, et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2012;118(15):3703-9.
45. Novick PA, Ortiz OF, Poelman J, et al. SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computer-aided drug discovery. PLoS One 2013;8(11):e79568.
46. Swamidass SJ. Mining small-molecule screens to repurpose drugs. Brief Bioinform 2011;12(4):327-35.
47. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28(1):235-42.
48. Pihan E, Colliandre L, Guichou JF, et al. e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment- based drug design. Bioinformatics 2012;28(11):1540-4.
49. Wang Y, Chen S, Deng N, et al. Drug repositioning by kernelbased integration of molecular structure, molecular activity, and phenotype data. PLoS One 2013;8(11):e78518.
50. Tan FJ, Yang RZ, Xu XX, et al. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity. Mol Biosyst 2014;10(5):1126-38.
51. Ng C, Hauptman R, Zhang Y, et al. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems biology approach. Pac Symp Biocomput 2014:136-47.
52. Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci USA 2014;111(31):11365-70.
53. Wu M, Sirota M, Butte AJ, Chen B. Characteristics of drug combination therapy in oncology by analyzing clinical trial data on clinicaltrials.gov. Pac Symp Biocomput 2015;20 68-79.
54. Huang H, Zhang P, Qu XA, et al. Systematic prediction of drug combinations based on clinical side-effects. Sci Rep 2014;4:7160.
55. Sun Y, Xiong Y, Xu Q, et al., A hadoop-based method to predict potential effective drug combination. Biomed Res Int 2014:196858.
56. Liu Y, Hu B, Fu C, et al. DCDB: drug combination database. Bioinformatics 2010;26(4):587-8.
57. Kang Y, Hodges A, Ong E, et al. Identification of drug combinations containing imatinib for treatment of BCR-ABLρ Leukemias. PLoS One 2014;9(7):e102221.
58. Menden MP, Iorio F, Garnett M, et al. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One 2013;8(4):e61318.
59. Napolitano F, Zhao Y, Moreira VM, et al. Drug repositioning: a machine-learning approach through data integration. J Cheminform 2013;5:30.
60. Gottlieb A, Stein GY, Ruppin E, et al. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 2011;7:496.
61. Zhang P, Wang F, Hu J. Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. AMIA Annu Symp Proc 2014:1258-67.
62. Yang J, Li Z, Fan X, et al. Drug-disease association and drugrepositioning predictions in complex diseases using causal inference-probabilistic matrix factorization. J Chem Inf Model 2014;54(9):2562-9.
63. Yildirim MA, Goh KI, Cusick ME, et al. Drug-target network. Nat Biotechnol 2007;25(10):1119-26.
64. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009;461(7261):218-23.
65. Iorio F, Saez-Rodriguez J, di Bernardo D. Network based elucidation of drug response: from modulators to targets. BMC Syst Biol 2013;7:139.
66. Li J, Lu Z. A new method for computational drug repositioning using drug pairwise similarity. Proc IEEE Int Conf Bioinformatics Biomed 2012;2012:1-4.
67. Li J, Lu Z. Pathway-based drug repositioning using causal inference. BMC Bioinformatics 2013;14 (Suppl 16): S3.
68. Wu C, Gudivada RC, Aronow BJ, et al. Computational drug repositioning through heterogeneous network clustering. BMC Syst Biol 2013;7:S6.
69. Jin G, Fu C, Zhao H, et al. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res, 2012;72(1):33-44.
70. Lu Z. PubMed and beyond: a survey of web tools for searching biomedical literature. Database (Oxford) 2011;2011: baq036.
71. Islamaj Dogan R, Murray GC, Neveol A, et al. Understanding PubMed user search behavior through log analysis. Database (Oxford) 2009;2009:bap018.
72. Leaman R, Islamaj Dogan R, Lu Z. DNorm: disease name normalization with pairwise learning to rank. Bioinformatics 2013;29(22):2909-17.
73. Li J, Lu Z. Systematic identification of pharmacogenomics information from clinical trials. J Biomed Inform 2012;45(5): 870-8.
74. Leaman R, Wei CH, Lu Z. tmChem: a high performance approach for chemical named entity recognition and normalization. J Cheminform 2015;7 (Suppl 1): S3.
75. Wei CH, Kao HY, Lu Z. PubTator: a web-based text mining tool for assisting biocuration. Nucleic Acids Res 2013;41 (Web Server issue):W518-22.
76. Arighi CN, Wu CH, Cohen KB, et al. BioCreative-IV virtual issue. Database (Oxford) 2014;2014:bau-039.
77. Tari LB, Patel JH. Systematic drug repurposing through text mining. Methods Mol Biol 2014;1159:253-67.
78. Andronis C, Sharma A, Virvilis V, et al. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform 2011;12(4):357-68.
79. Zhu Q, Tao C, Shen F, et al. Exploring the pharmacogenomics knowledge base (PharmGKB) for repositioning breast cancer drugs by leveraging Web ontology language (OWL) and cheminformatics approaches. Pac Symp Biocomput 2014: 172-82.
80. Chen B, Ding Y, Wild DJ. Assessing drug target association using semantic linked data. PLoS Comput Biol 2012;8(7): e1002574.
81. Zerbini LF, Bhasin MK, de Vasconcellos JF, et al. Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Mol Cancer Ther 2014;13(7): 1929-41.
82. Vegner L, Peragovics A, Tombor L, et al. Experimental confirmation of new drug-target interactions predicted by drug profile matching. J Med Chem 2013;56(21):8377-88.
83. Khatri P, Roedder S, Kimura N, et al. A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J Exp Med 2013;210(11):2205-21.
84. Xu H, Aldrich MC, Chen Q, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc 2015;22:179-91.
85. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110(9):3507-12.
86. Takao K, Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2015;112(4):1167-72.
87. Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013;4:2126.
88. Pessetto ZY, Weir SJ, Sethi G, et al. Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther 2013;12(7): 1299-309.
89. Stenvang J, Kumler I, Nygard SB, et al. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol 2013;3:313.
90. Nygren P, Fryknas M, Agerup B, et al., Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J Cancer Res Clin Oncol 2013;139(12):2133-40.
91. Quinn BJ, Kitagawa H, Memmott RM, et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013;24(9):469-80.
92. Yeh CT, Wu AT, Chang PM, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med 2012;186(11):1180-8.
93. Molineris I, Ala U, Provero P, et al. Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs). BMC Bioinformatics 2013;14:288.
94. Xu K, Cote TR. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief in Bioinform 2011;12(4):341-5.
95. Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013;3(12):1416-29.
96. Li YY, Jones SJ. Drug repositioning for personalized medicine. Genome Med 2012;4(3):27.
97. Iskar M, Campillos M, Kuhn M, et al. Drug-induced regulation of target expression. PLoS Comput Biol 2010;6(9).
98. Khare R, Li J, Lu Z. LabeledIn: cataloging labeled indications for human drugs. J Biomed Inform 2014;52:448-56.
99. Khare R, Burger JD, Aberdeen JS, et al. Scaling drug indication curation through crowdsourcing. Database 2015; 2015:bav016. doi:10.1093/database/bav016
100. Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci 2014;10(7): 654-63.
101. Enserink M. Infectious diseseases. Debate erupts on 'repurposed' drugs for Ebola. Science 2014;345(6198):718-19.